Debrecen Pharma R&D (RSFF)

The project concerns financing the R&D for new Active Pharmaceutical Ingredients (APIs), innovative drug compounds and new generic drugs located in Debrecen, Gödöllö and Sajobabony, as well as two related capital expenditure investments in R&D Centres in Debrecen and Gödöllö.

Objectives

The aim of the first, R&D part of the project is the commercialisation of more than 30 new generic compounds up to 2013. The purpose of the capital expenditure investments is to increase the existing R&D infrastructure.

Comments

Sector(s)

Industry

Proposed EIB finance (Approximate amount)

EUR 100 million.

Total cost (Approximate amount)

EUR 200 million.

Environmental aspects

Installations for the R&D Centre in Debrecen will fall under Annex II of the EIA Directive 85/337/EEC, amended by Directives 97/11/EC and 2003/35/EC. Whether the competent authorities have required an EIA or not will be verified during appraisal, as well as any actual/possible significant impacts on protected flora and fauna (Habitats and Birds Directives). Compliance of R&D activities with relevant EU legislation in regards to animal testing, clinical trials, etc. will be verified during appraisal.

Procurement

The promoter is a private company not operating in the Utilities sector, and is thus not covered by EU Directives 2004/18/EC. The promoter carries out competitive international consultations among potential suppliers for goods and services, which is standard practice for this industry.

Status

Signed - 24/09/2009.

Disclaimer

Before financing approval by the Board of Directors, and before loan signature, projects are under appraisal and negotiation. Therefore data provided on this page is indicative and cannot be considered to represent official EIB Policy (see also the Explanatory notes).

Projects

R&D in Debrecen, Gödöllö and Sajóbábony aimed at manufacturing drugs and new active pharmaceutical ingredients (APIs)

E-mail

General enquiries and comments

The EIB is committed to open communication and encourages constructive stakeholder input regarding its activities. Enquiries and comments regarding the EIB’s involvement in a project or the financing facilities, activities, organisation and objectives of the EIB, can be sent to the EIB Infodesk.

Alternatively, EIB can also be contacted through its external offices.

Queries regarding details of a specific project, in particular when EIB loan is under appraisal, should be preferably addressed directly to project promoters.

Media enquiries

Media related enquiries can be addressed to the EIB Press Office. Please also visit our Press Corner.

Complaints mechanism

Any complaint regarding alleged maladministration can be lodged to EIB Complaints Mechanism. The European Ombudsman acts as an independent external accountability mechanism of the EIB.

Zero-tolerance against fraud and corruption

The EIB has a zero-tolerance policy on fraud or corruption. To report allegations of fraud or corruption in EIB-financed projects, please contact the Fraud and Investigation division. All complaints will be treated as strictly confidential, and are handled in line with EIB investigation procedures and the Anti-Fraud Policy.

EIB Transparency Policy

The EIB is committed to achieving the highest possible level of transparency. The EIB Transparency Policy sets out how EIB discloses information and consults with its stakeholders so as to promote better awareness and understanding of its strategies, policies and operations.

Guide to procurement

This Guide applies specifically to those components of a project identified for the Bank's financing.